<DOC>
	<DOCNO>NCT00589784</DOCNO>
	<brief_summary>The purpose study find effect , good and/or bad , sunitinib patient tumor . At time , drug routinely use treat meningioma , hemangioblastoma hemangiopericytoma . Only surgery radiation therapy know useful . Sunitinib drug approve advanced kidney cancer . Sunitinib also study tumor . It may useful treatment brain tumor prevent formation new blood vessel allow tumor cell survive grow .</brief_summary>
	<brief_title>Phase II Trial Sunitinib ( SU011248 ) Patients With Recurrent Inoperable Meningioma</brief_title>
	<detailed_description>This phase II study Sunitinib patient recurrent inoperable meningioma . An exploratory study perform patient recurrent hemangiopericytoma hemangioblastoma . There approximately 50 patient enrol study ( 40 meningiomas 10 hemangiopericytomas/hemangioblastomas ) . The treatment plan use daily SU11248 dose 50 mg , use establish schedule 4 week treatment follow two week rest period , form six-week treatment cycle . A medical professional see patient least every six week medication toxicity assessment physical examination . Extent disease evaluation occur baseline , two week , twelve week , 24 week , every twelve week thereafter . These evaluation include MRI brain ( CT head patient undergo MRI ) MR perfusion .</detailed_description>
	<mesh_term>Meningioma</mesh_term>
	<mesh_term>Neurofibromatoses</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Hemangiopericytoma</mesh_term>
	<mesh_term>Hemangioblastoma</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Cytochrome P-450 CYP3A Inducers</mesh_term>
	<criteria>Histologically proven recurrent meningioma intracranial hemangiopericytoma hemangioblastoma . This include benign , atypical , malignant meningioma ; patient neurofibromatosis type 1 2 may participate . Patients classic radiographic picture meningioma may also enroll surgically accessible . In instance patient must review multidisciplinary brain tumor conference include neurosurgery neuroradiology determine patient appropriate study . Unequivocal evidence tumor progression MRI ( CT scan MRI contraindicate ) . The scan must perform within 14 day registration . Steroids dose malignant meningioma must stable dose least 5 day prior baseline image . For patient benign atypical meningioma , stable steroid dos require . Recent resection recurrent tumor patient eligible long recovered effect surgery residual disease evaluate . To best assess extent residual disease postoperatively , CT/MRI do later 96 hour immediate postoperative period least 4 week postoperatively . If 96 hour scan 14 day registration , repeat . Because Sunitinib VEGF inhibitor carry many risk include thrombocytopenia , bleeding , hypertension , stroke , patient must wait least 14 day surgery , without complication , may initiate study drug . Prior radiation therapy patient may treat standard external beam radiation , interstitial brachytherapy , radiosurgery combination . An interval ≥ 4 week ( 28 day ) must elapse completion radiation therapy study entry must subsequent evidence tumor progression . Patients prior interstitial brachytherapy stereotactic radiosurgery must confirmation true progressive disease rather radiation necrosis base PET , MR spectroscopy surgical documentation disease . Patients prior surgery radiotherapy meningioma review multidisciplinary brain tumor conference include neurosurgery radiation oncology determine patient appropriate study . Prior therapy : There limitation number prior surgery , radiation therapy , radiosurgery treatment , chemotherapy . All patient must sign informed consent indicate aware investigational nature study . Patients must sign authorization release protect health information . Age ≥ 18 year old Karnofsky performance status ≥ 60 % . ≥ 4 week since prior RT , stereotactic radiosurgery , chemotherapy . Required Initial Laboratory Values ( within 14 day registration ) : Absolute neutrophil count ( ANC ) ≥ 1,000/mm3 Platelets ≥ 100,000/mm3 hemoglobin ≥ 8gm/dl Serum aspartate transaminase ( AST ; serum glutamic oxaloacetic transaminase [ SGOT ] ) serum alanine transaminase ( ALT ; serum glutamic pyruvic transaminase [ SGPT ] ) ≤ 2.5 x local laboratory upper limit normal ( ULN ) Creatinine ≤ 2.0 mg/dl PT , INR , PTT ≤ 1.5 time institutional upper limit normal Total serum bilirubin ≤ 1.5 Patients history NF may stable CNS tumor , schwannoma , acoustic neuroma , ependymoma , ONLY lesions stable size precede 6 month . Patients history cancer ( except nonmelanoma skin cancer carcinoma insitu cervix , unless complete remission therapy disease minimum 3 year ) ineligible . Any prior TKI therapy ( SU011248 , Sorafenib , Semaxinib , Axitinib ) Concomitant use investigational drug Concomitant use enzymeinducing antiepileptic drug . Concomitant use St John 's Wort . Any follow within 6 month prior study drug administration : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism . Ongoing cardiac dysrhythmias NCI CTCAE Version 3.0 grade ≥ 2 . Prolonged QTc interval baseline EKG ( &gt; 450 msec male &gt; 470 msec female ) . Uncontrolled hypertension ( &gt; 150/100 mm Hg despite optimal medical therapy ) . Patients exclude elevated diastolic , elevate systolic , . History intracranial hemorrhage . Preexisting thyroid abnormality , thyroid function test maintain normal range medication . Known human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness active infection . Concurrent treatment another clinical trial . Supportive care trial nontreatment trial , e.g . QOL , allow . Ongoing treatment therapeutic dos warfarin ( low dose warfarin 2 mg daily thromboembolic prophylaxis allow ) . Pregnancy breastfeed . Patients must surgically sterile , postmenopausal , agree use effective contraception period therapy . The definition effective contraception base judgment principal investigator designate associate . Male patient must surgically sterile agree use effective contraception . Women childbearing potential must negative BHCG pregnancy test document within 14 day prior registration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Sunitinib</keyword>
	<keyword>Brain Cancer</keyword>
	<keyword>CNS Cancer</keyword>
	<keyword>meningioma</keyword>
	<keyword>intracranial hemangiopericytoma</keyword>
	<keyword>hemangioblastoma</keyword>
	<keyword>malignant meningioma</keyword>
	<keyword>neurofibromatosis</keyword>
	<keyword>neurofibromatosis type 1</keyword>
	<keyword>neurofibromatosis type 2</keyword>
	<keyword>07-135</keyword>
</DOC>